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Abstract
Background: After the global implementation of national immunization programs for prevention of measles, mumps,
and rubella (MMR), the prevalences of protective antibodies to these viruses are high in general population. However,
there are limited data among human immunodeficiency virus (HIV)-1 infected individuals. This study aimed to determine
the seroprevalence of antibodies to these viruses, and the serologic responses after vaccination among HIV-infected
adults in Northern Thailand.
Methods: A cross-sectional study was conducted in 500 HIV-infected adults, aged 20–59 years, receiving combination
antiretroviral therapy, CD4 cell count ≥200 cells/mm3, and plasma HIV-1 RNA <50 copies/mL, and 132 HIV-uninfected
controls, aged 20–59 years, at Chiang Mai University Hospital during July and August 2011. Prevalences of protective
antibodies to these viruses as well as serologic responses after MMR vaccination in those without protective antibody
to at least one of the three viruses were compared between groups.
Results: The prevalences of protective antibodies to measles, mumps, and rubella were 94.2, 55.0, and 84.6 % among
HIV-infected adults, and 97.7, 67.5, and 89.4 % among HIV-uninfected controls, respectively. The prevalence of protective
antibody to mumps was significantly lower in HIV-infected adults (p-value = 0.010). MMR vaccination was done in 249
HIV-infected and 46 HIV-uninfected controls; at week 8 to 12 after vaccination, the seroprotective rates against measles,
mumps, and rubella in HIV-infected adults were 96.4, 70.7, and 98.0 %, respectively, whereas those in HIV-uninfected
controls were 100, 87, and 100 %, respectively. No serious adverse effects were observed.
Conclusions: In contrast to measles and rubella, the prevalence of protective antibody to mumps was low in both
HIV-infected adults and HIV-uninfected controls in northern Thailand. The seroprotective rates after MMR vaccination in
both groups were considerably high, except only for mumps. Therefore, MMR vaccination should be considered in all
HIV-infected adults receiving antiretroviral therapy with undetectable plasma HIV-1 RNA and CD4 cell count ≥200 cells/
mm3.
Trial registration: ClinicalTrials.gov: NCT02724852, registered on March 31, 2016.
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Background
Measles, mumps, and rubella have long been regarded as
diseases of childhood [1–3]. However, when infections
from these viruses occur in adults, they are often more
severe [1–3]. The serious complications may occur par-
ticularly in pregnant women [2]. The incidence of measles,
mumps, and rubella has decreased dramatically in coun-
tries where measles, mumps, and rubella (MMR) vaccin-
ation is integrated into the national immunization
program, including Thailand [4–6]. The first dose of
measles vaccination in children aged 9–12 months and
the second dose in first grade students were incorporated
into the Thai national immunization program in 1984 and
1996, respectively. Rubella vaccination in first grade
students was incorporated into the program 1993. The
vaccine against single virus was replaced by MMR vaccine
in 1997 [7]. The Thai national survey in 2003 and 2004
showed that the coverages of the first dose of measles
vaccine among children aged 9–12 months and MMR
vaccine among the first grade students were 96 and 94 %,
respectively [8, 9]. In general, measles vaccination pro-
duces protective antibody in 88–95 % of children [10, 11].
The seroprevalence study among Thai population in 2004
revealed that 81 % (95 % CI 78.8–83.5) of 1092 serum
specimens tested, 89 % (95 % CI 86.8–91.0) of 899 speci-
mens tested, and 82 % (95 % CI 78.9–84.0) of 911 speci-
mens tested had protective antibody to measles, mumps,
and rubella, respectively [6]. Although the vaccine cover-
age and the rate of protective antibody to these viruses are
quite high in Thai population, periodic outbreaks have
been reported and might be attributed to the waning of
antibody after a long period of time [12].
A study in Thai HIV-infected children receiving combin-
ation antiretroviral therapy (cART) reported that the preva-
lence of protective antibody to measles was only 42 % [13].
A study among HIV-infected adults in the United States
reported that the prevalences of protective antibodies to
measles, mumps, and rubella were 67, 91, and 95 %, re-
spectively [14]. MMR revaccination has been studied in
Thai children aged over 5 years and had CD4 > 15 % for at
least 3 months after receiving cART. The study showed that
the seroprotective rates against measles, mumps, and ru-
bella declined overtime after vaccination [15]. In adults, a
study in Mexico showed the early loss of measles antibody
after 24 months of vaccination despite receiving cART [16].
These evidence suggested that loss of antibody responses
may occur in HIV-infected people after vaccination, par-
ticularly in advanced diseases.
Up to date, there have been limited data regarding the
prevalences of protective antibodies to measles, mumps,
and rubella among Thai HIV-infected adults. We, therefore,
conducted this study to determine 1) the prevalences of
protective antibodies to measles, mumps, and rubella in
HIV-infected adults and HIV-uninfected controls in
northern Thailand, 2) the serologic responses at 8 to
12 weeks, and 48 weeks after MMR vaccination in those
without protective antibody to at least one of the three
viruses, and 3) adverse effects of MMR vaccination.
Methods
Study design, and population
The first phase of the study was a cross-sectional study
to determine the prevalences of MMR-specific anti-
bodies in HIV-infected adults and HIV-uninfected con-
trols. HIV-infected adults receiving care at the HIV
clinic of the Chiang Mai University Hospital between
July and August 2011 and met the following criteria
were consecutively enrolled: 1) 20–59 years old, 2) re-
ceiving cART, 3) CD4 cell count ≥200 cell/mm3 within
6 months before enrolment, 4) plasma HIV-1 RNA <50
copies/mL, and 5) ability to provide written informed
consent. HIV-uninfected controls, aged 20–59 years,
were recruited from their relatives, hospital visitors,
and hospital personnel, during the same period. Partici-
pants with following conditions were excluded: 1)
pregnancy or lactating, 2) receiving cancer treatment,
organ transplantation, ≥0.5 mg/kg/day of prednisolone
or equivalent, or immunomodulating treatment, 3) im-
paired renal function (creatinine clearance <30 mL/
min), and 4) impaired liver function as defined by
Child-Pugh C.
All participants who had no protective antibody to at
least one of the three viruses were recruited into the second
phase of the study. In this phase, participants were vacci-
nated with a single dose of MMR vaccine (GlaxoSmithKline
Biologicals) at deltoid region by WK. Each 0.5 ml of vaccine
contained at least 1000 TCID50 of Schwarz measles strain,
at least 1000 TCID50 of RIT 4385 mumps, and at least
1000 TCID50 of Wistar RA 27/3 rubella strains. Antibodies
to MMR were measured at week 8 to12, and week 48 after
vaccination.
Sample size calculation
Based on a previous study in Thai adults aged ≥25 years,
the prevalences of seroprotective antibody to measles,
mumps, and rubella were 90.6–96.3 %, 86.2–94.9 %, and
85.6–96.9 %, respectively [6]. We estimated that the preva-
lence of protective antibody to each of these viruses was
80 % among HIV-infected adults and 94 % among HIV-
uninfected controls. For the first phase of the study, a
sample size of 103 per group was required to significantly
detect differences between them, at the power of 80 %
using a cutoff for a two-sided alpha level of 0.05. However,
we over-enrolled participants in both groups in order to
have adequate number of participants without protective
antibody for the second phase of the study.
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Data collection
Demographic and clinical data were collected using a pre-
printed data collection form including age, sex, recall of
prior measles, mumps, or rubella vaccination, anti-measles
IgG antibody level, anti-mumps IgG antibody titer, and
anti-rubella IgG antibody level at the time of enrolment.
The levels of antibody to the three viruses were also mea-
sured at 8 to 12 weeks, and 48 weeks after vaccination in
those who were enrolled into the second phase of the study.
In addition, CD4 cell count and plasma HIV-1 RNA within
6 months before enrolment were collected for all HIV-
infected adults. Local and systemic adverse effects of the
vaccine were also collected.
Measurement of antibody levels to measles, mumps, and
rubella
Laboratory tests were performed at the National Institute of
Health, Department of Medical Sciences, Ministry of Public
Health, Bangkok, Thailand. The indirect ELISA using Enzyg-
nost® Anti-Measles Virus/IgG, Anti-Parotitis-Virus/IgG,
Anti-Rubella-Virus-IgG (Siemens, Marburg, Germany) were
performed following the manufacturer’s instructions. The
optical density (OD) readings were interpreted as negative,
equivocal, and positive if the delta OD was <0.1 (cut off),
0.1–0.2, and >0.2, respectively. Positive delta ODs were then
converted to international units, as described in the package
insert [17–19]. Protective antibody levels were defined as an
antibody level ≥320 mIU/mL, antibody titer ≥1:500, and anti-
body level ≥10 IU/mL for measles, [10] mumps, [20] and
rubella, respectively [21].
Statistical analysis
Data were presented in mean ± SD, median and IQR, num-
ber (%) as appropriate. Continuous variables were compared
using Student’s t-test or Mann Whitney-U test, and categor-
ical variables were compared using Chi-2 test and Fisher’s
exact test. Statistical significance was set as 2-tailed, with p-
value of <0.05. The Bonferroni correction was used for multiple
comparisons. All statistical analyses were performed using Stata
statistical software version 11.0 (Stata Statistical Software:
Release 11.0, Stata Corporation, College Station, TX, 2009).
The study was approved by the Faculty of Medicine, Chiang
Mai University Ethical Committee. The trial was registered to
the ClinicalTrials.gov (NCT02724852) on March 31, 2016.
Results
Seroprevalence of antibodies to measles, mumps, and
rubella
Five hundred HIV-infected adults and 132 HIV-uninfected
controls were enrolled. Among HIV-infected adults, 218
(43.6 %) were male; the median age was 41 years (IQR 36,
48), and the median CD4 cell count was 470 cells/mm3
(IQR 364, 594). Among HIV-uninfected adults, 35 were
male (26.5 %), and the median age was 38 years (IQR 30.5,
48). Characteristics of HIV-infected adults and HIV-
uninfected controls are shown in Table 1.
The prevalences of protective antibodies to measles,
mumps, and rubella and the antibody levels across age groups
are shown in Tables 2 and 3, respectively. Among HIV-
infected adults, the prevalence of protective antibody to mea-
sles was significantly lower among adults aged 20–29 years
than other age groups (p-values < 0.05). There were no differ-
ences of the prevalence of protective antibody to mumps
across age groups. The prevalence of protective antibody to
rubella was lower among adults aged 40–49 years than aged
30–39 (p-value = 0.016), and 50–59 years (p-value = 0.035).
However, overall, there were no differences in prevalences of
protective antibodies to all three viruses across all age groups.
Among HIV-uninfected controls, there were also no differ-
ences in prevalences of protective antibodies to all three vi-
ruses across all age groups. However, we observed a higher
anti-mumps IgG titer among those aged 50–59 years than all
other age groups (p-values < 0.05).
Although the prevalence of protective antibody to
mumps was lower in HIV-infected adults than in HIV-
uninfected controls (p-value = 0.010), there were no differ-
ences in the prevalences of protective antibodies to all three







Male 218 (43.5) 35 (26.5) <0.001







Yes 60 (12.0) 12 (9.1)
No 231 (46.2) 9 (6.8)




Yes 39 (7.8) 6 (4.6)
No 454 (90.8) 126 (95.5)




Yes 12 (2.4) 2 (1.5)
No 481 (96.2) 128 (97.0)




Yes 2 (0.4) 3 (2.3)
No 491 (98.2) 129 (97.7)
Uncertain 7 (1.4) 0 (0)
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viruses between HIV-infected adults and HIV-uninfected
controls in all age groups. The antibody levels against
measles were significantly higher in HIV-uninfected
controls than HIV-infected adults in those aged
30–39 years. The antibody titers against mumps and the
antibody levels against rubella were not different
between HIV-infected and HIV-uninfected controls in
all age groups.
Serologic responses after vaccination
There were 269 HIV-infected adults and 51 HIV-
uninfected controls who had no protective antibody to at
least one of the three viruses. Two-hundred and forty-
nine HIV-infected adults and 46 HIV-uninfected controls
were recruited into the second phase of the study. (Fig. 1)
The reasons for not participating in the second phase of
the study among 20 HIV-infected adults included 1) de-
tectable plasma HIV-1 RNA (4 participants), 2) pregnancy
(1), 3) diagnoses of lung cancer (1), cancer of tongue (1),
and non-Hodgkin’s lymphoma (1), 4) being referred to
other hospitals (4), 5) lost to follow up (2), 6) enrolment
to other clinical trials (3), 7) >59 years old at the time of
enrolment to the second phase (2), and 8) self-withdrawal
from the study (1). The reasons in those five HIV-
uninfected controls included 1) moving to other provinces
(2), 2) diagnosis of cholangioarcinoma (1), 3) >59 years
old (1), and 4) self-withdrawal from the study (1). Two
HIV-infected adults were not tested for serologic responses
at the 48th week; one patient died at home 32 weeks after
vaccination and the other was lost to follow up.
One hundred and six of 249 HIV-infected adults and 13
of 46 HIV-uninfected controls were male (p-value 0.074).
The median age of HIV-infected adults was 41 years (IQR
35, 46) and that of HIV-uninfected controls was 38 years
(IQR 31, 45) (p-value = 0.044). The median CD4 cell count
among HIV-infected adults was 455 cells/mm3 (IQR 355,
589). The prevalences of protective antibodies against
measles, mumps, and rubella at baseline and after vaccin-
ation in HIV-infected adults and HIV-uninfected controls
are shown in Table 4. Among HIV-infected adults, 11, 83,
and 30 % had no protective antibodies against measles,
mumps, and rubella, respectively. For HIV-uninfected
controls, 5, 65 and 24 % had no protective antibodies
against measles, mumps, and rubella, respectively.
After vaccination, overall, there were no differences
between HIV-infected adults and HIV-uninfected controls
in the seroprotective rates against all three viruses. For
mumps, the seroprotective rates were lower among HIV-
infected adults at baseline (p-value = 0.005), at 8–12 weeks
(p-value = 0.022), and at 48 weeks after vaccination (p-value
= 0.061). For those who had no protective antibody at base-
line, the seroprotective rates was higher among HIV-
uninfected controls than HIV-infected adults at 8–12 weeks
(p-value = 0.007) and 48 weeks after vaccination (p-value =
0.039).
Adverse effects of vaccination
Adverse effects during the first 72 h after vaccination in-
cluded pain at the injection site (ten participants, 3.4 %),
fatigue (8, 2.7 %), headache (7, 2.4 %), fever (6, 2.0 %), and
local reactions at the injection site (3, 1.0 %). All these
adverse effects resolved spontaneously without treatment.
Discussion
This study demonstrated that in northern Thailand, the
prevalence of seroprotective antibody to mumps in healthy
adults was significantly lower than those to measles and
rubella. These findings are similar to those in the study
among healthy adults from northern Greece where the
prevalence of seroprotective antibody to mumps was lower
than that to measles [22]. However, our findings are differ-
ent from those in the study among Thai adults in which
the prevalences of seroprotective antibodies to all three
viruses were comparably high [6]. Among HIV-infected
adults, we found that the prevalence of seroprotective anti-
body as well as the level of antibody to mumps were signifi-
cantly lower than those to measles and rubella. These
findings are similar to those in studies among HIV-infected
children in Thailand, [15] HIV-infected adults in England
[23] and Austria,[24] but in contrast with findings in the
study from the US where the prevalence of seroprotective
antibody to measles was the lowest [14]. The differences
among studies might be explained by the difference in the
national vaccination program and also the prevalence of



















20–29 19/24 (79.2) 28/30 (93.3) 0.221 15/24 (62.5) 20/30 (66.7) 0.781 23/24 (95.8) 29/30 (96.7) 1.000
30–39 186/192 (96.9) 42/42 (100) 0.595 101/192 (52.6) 29/42 (69.1) 0.060 168/192 (87.5) 36/42 (85.7) 0.799
40–49 170/182 (93.4) 29/30 (96.7) 0.699 95/182 (52.2) 17/30 (56.7) 0.697 142/182 (78.0) 25/30 (83.3) 0.634
50–59 96/102 (94.1) 30/30 (100) 0.336 64/102 (62.8) 23/30 (76.7) 0.192 90/102 (88.2) 28/30 (93.3) 0.736
Overall 471/500 (94.2) 129/132 (97.7) 0.120 275/500 (55.0) 89/132 (67.5) 0.010 423/500 (84.6) 118/132 (89.4) 0.209
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Table 3 IgG antibody levels to measles, antibody titers to mumps, and antibody levels to rubella in HIV-infected adults and HIV-uninfected controls across age groups
Age group (years) Anti-measles IgG level (mIU/mL) Anti-mumps IgG titer (titer 1:xxxx) Anti-rubella IgG level (IU/mL)
HIV-infected adults HIV-uninfected controls p-value HIV-infected adults HIV-uninfected controls p-value HIV-infected adults HIV-uninfected controls p-value
20–29 1743 (1101, 6816) 4383.5 (1526, 6195) 0.399 919 (202, 2009.5) 976 (414, 1588) 0.803 44.5 (18.5, 86) 44.5 (21, 73) 0.741
30–39 3327 (1636, 5378) 5015 (2724, 6652) 0.007 605 (220, 1546) 967 (403, 1664) 0.064 43.5 (18, 105) 28 (14, 60) 0.071
40–49 2949 (1416, 6010) 5023.5 (2990, 7735) 0.345 552 (138.5, 1522) 720.5 (174, 1558) 0.777 41 (12, 106) 52 (12, 70) 0.976
50–59 3115.5 (1568, 5737) 5938 (2591, 6986) 0.066 905.5 (315.5, 2199.5) 1273.5 (533, 2716) 0.074 54 (17, 101.5) 59.5 (13, 103) 0.879















natural infection in each community. In Thailand, as previ-
ously described, measles vaccine and rubella vaccine were
incorporated to the national vaccination program in 1984
and 1993, respectively, while MMR vaccine replaced
vaccines for single virus in 1997. Therefore, the prevalence
of seroprotective antibody to mumps would be lower than
those for measles and rubella. Interestingly, a study among
Thai population in 2004 revealed that the prevalence of
seroprotective antibody to mumps was more than 80 %,
and comparable to those to measles and rubella; this high
prevalence of antibody to mumps corresponded with the
transmission of mumps virus during that period [6, 12].
We found that there were no differences in the
prevalences of seroprotective antibodies to all three
viruses across all age groups for both HIV-infected
adults and HIV-uninfected controls. In addition, there was
no difference in the prevalences of seroprotective
antibodies to all three viruses between HIV-infected
adults and HIV-uninfected controls in each age
group. However, this must be interpreted with caution
from the small number of participants in each age
group.
In the second phase of our study to determine the sero-
logical responses to MMR vaccination in participants who
had no protective antibody to any of the three viruses, we
found that the prevalence of seroprotective antibody to
measles at baseline were very high in both HIV-infected
adults and HIV-uninfected controls. Therefore, minority
of them required measles vaccination. Among HIV-
infected adults, the seroprotective rate against measles
and mumps at 8 to 12 weeks after MMR vaccination was
lower among those who had no protective antibody at
baseline compared to those who had protective antibody
at baseline (p-value < 0.001). The immunity to measles
and mumps persisted through week 48 after vaccination
for those who had protective antibody at baseline but not
for those who had no protective antibody at baseline.
These findings are similar to the studies among HIV-
infected Thai children and HIV-infected adults in Mexico
[15, 16]. However, we found that the seroprotective rate
against rubella after MMR vaccination was almost 100 %
and the immunity to rubella persisted through week 48.
The excellent antibody response to the rubella component
of MMR vaccine has been shown in several studies among
Fig. 1 Flow of participants
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Table 4 Prevalences of protective antibodies to measles, mumps, and rubella after vaccination in HIV-infected adults and HIV-uninfected controls
HIV-infected adults HIV-uninfected controls
Baseline Week 8–12 Week 48 Baseline Week 8–12 Week 48
Measles
Presence of protective antibody
to measles
All 222/249 (89.2) 240/249 (96.4) 234/247 (94.7) 44/46 (95.7) 46/46 (100) 44/46 (95.7)
Detectable baseline protective
antibody to measles
- 220/222 (99.1) 219/220 (99.6) - 44/44 (100) 43/44 (97.7)
No baseline protective antibody
to measles
- 20/27 (74.1) 15/27 (55.6) - 2/2 (100) 1/2 (50)
Anti-measles IgG level (mIU/mL)
All 2654 (1132, 4768) 2771 (1315, 4911) 2604 (1208, 5061) 3353.5 (2035, 5834) 3221.5 (1367, 5232) 2863.5 (1659, 5164)
Detectable baseline protective
antibody to measles
2946 (1560, 5082) 3022.5 (1674, 5225) 2993 (1572.5, 5291) 3450.5 (2215, 5970.5) 3254.5 (1427.5, 5313.5) 2977 (1720.5, 5508.5)
No baseline protective antibody
to measles
200 (148, 269) 616 (289, 2049) 394 (228, 961) 137 (129, 145) 1791.5 (342, 3241) 965.5 (226, 1705)
Mumps
Presence of protective antibody
to mumps
All 42/249 (16.9)* 176/249 (70.7)** 182/247 (73.7)*** 16/46 (34.8)* 40/46 (87.0)** 40/46 (87.0)***
Detectable baseline protective
antibody to mumps
- 40/42 (95.2) 42/42 (100) - 13/16 (81.3) 14/16 (87.5)
No baseline protective antibody
to mumps
- 136/207 (65.7)**** 140/205 (68.3)***** - 27/30 (90)**** 26/30 (86.7)*****
Anti-mumps IgG titer (1:xxxx)
All 220 (61, 431) 1086 (423, 2818) 886 (457, 1820) 247 (107, 399) 1821 (1223, 3375) 1191.5 (696, 1997)
Detectable baseline protective
antibody to mumps
1221 (785, 2765) 2550 (1198, 4523) 1836.5 (1089, 3443) 474 (148, 890) 2280 (1278, 4006) 1653 (804, 2054.5)
No baseline protective antibody
to mumps















Table 4 Prevalences of protective antibodies to measles, mumps, and rubella after vaccination in HIV-infected adults and HIV-uninfected controls (Continued)
Rubella
Presence of protective antibody
to rubella
All 174/249 (69.9) 244/249 (98.0) 241/247 (97.6) 35/46 (76.1) 46/46 (100) 46/46 (100)
Detectable baseline protective
antibody to rubella
- 174/174 (100) 171/172 (99.4) - 35/35 (100) 35/35 (100)
No baseline protective antibody
to rubella
- 70/75 (93.3) 70/75 (93.3) - 11/11 (100) 11/11 (100)
Anti-rubella IgG level (IU/mL)
All 27 (5, 74) 51 (27, 90) 47 (22, 87) 15 (7, 40) 47.5 (26, 86) 37 (21, 61)
Detectable baseline protective
antibody to rubella
47.5 (23, 99) 57.5 (27, 103) 42.5 (22, 91.5) 35 (21, 55) 47 (26, 86) 35 (21, 55)
No baseline protective antibody
to rubella
1 (1, 1) 45 (25, 68) 52 (23, 79) 1 (1, 7) 51 (11, 95) 42 (10, 42)















children [11, 15]. Our study found that most of the
adverse reactions from MMR vaccine were mild and self-
limited. None experienced serious adverse events.
Our study had some limitations. This study was not a pair-
matched case–control study; therefore, there were some
differences in baseline demographic characteristics between
groups. Compared to the HIV-infected adults, the HIV-
uninfected controls in our study were younger and had more
female; however, there were no significant differences in the
prevalences of seroprotective antibodies at baseline as well as
seroprotective rates to all three viruses after MMR vaccination
among different age groups and genders (data not shown). In
addition, we also found the imbalance in history of measles,
mumps, or rubella vaccination, and a recalled history of infec-
tions due to those viruses between groups. However, this im-
balance had no effect to the results since there were no
correlations between history of vaccination or recalled history
of infections due to those viruses with the prevalences of sero-
protective antibodies at baseline as well as seroprotective rates
to those viruses after MMR vaccination (data not shown).
Conclusions
This study demonstrated that in northern Thailand, the
majority of HIV-infected adults had protective antibody to
measles which is the most contagious virus among the
three virus components of MMR vaccine and can cause
serious complications. Lack of immunity against mumps
was more prevalent in our study. Seroprotective rates
against measles and mumps after MMR vaccination were
lower and the immunities persisted shorter in those who
had no protective antibody at baseline. Since the MMR
vaccine is safe and the history of prior vaccination or in-
fections are unreliable, MMR vaccination should be consid-
ered in all HIV-infected adults receiving antiretroviral
therapy who achieve undetectable plasma HIV-1 RNA and
CD4 cell count ≥200 cells/mm3.
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